Rankings
▼
Calendar
UTHR Q2 2016 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$413M
Gross Profit
$393M
95.2% margin
Operating Income
$285M
69.1% margin
Net Income
$206M
50.0% margin
EPS (Diluted)
$4.39
QoQ Revenue Growth
+11.8%
Cash Flow
Operating Cash Flow
$126M
Free Cash Flow
$115M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$2.2B
Total Liabilities
$384M
Stockholders' Equity
$1.8B
Cash & Equivalents
$838M
Revenue Segments
Remodulin
$159M
39%
Tyvaso
$107M
26%
Adcirca
$91M
22%
Orenitram
$38M
9%
Unituxin
$18M
4%
← FY 2016
All Quarters
Q3 2016 →
